Aardvark Therapeutics Q2 EPS $(0.66) Beats $(0.91) Estimate

Aardvark Therapeutics, Inc.

Aardvark Therapeutics, Inc.

AARD

0.00

Aardvark Therapeutics (NASDAQ: AARD) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.91) by 27.47 percent. This is unchanged from the same period last year.